1-6 of 6
Anthony Masaquel, MPH, PhD
Close
Sort by
Journal Articles

Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US?

Gregory F Guzauskas, MSPH, PhD, Anthony Masaquel, MPH, PhD, Per-Olof Thuresson, MSc, Jia Li, PhD, Carolina M Reyes, PhD, David Veenstra, PharmD, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5603.
https://doi.org/10.1182/blood.V130.Suppl_1.5603.5603
Published: 2017
Journal Articles

Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results from the Phase II GIBB Study of the Combination of Obinutuzumab and Bendamustine

Jeffrey P. Sharman, MD, Habte Yimer, MD, Michael Boxer, MD, Nicholas Di Bella, Sunil Babu, Jia Li, PhD, Yong Mun, Peter Trask, Anthony Masaquel, MPH, PhD, Carolina M Reyes, PhD, Alexey Danilov, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 683.
https://doi.org/10.1182/blood.V130.Suppl_1.683.683
Published: 2017
Journal Articles

Maintenance Rituximab after First Line Treatment in Veterans with Follicular Lymphoma Is Associated with Prolonged Overall Survival

Ahmad S. Halwani, MD, Kelli Rasmussen, MS, Vikas Patil, MS, Zach Burningham, PhD, Clarke Low, MD, Carolina M Reyes, PhD, Anthony Masaquel, MPH, PhD, Kevin Henderson, PharmD, MBA, Elisha Delong-Sieg, PharmD, Brian C Sauer, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1489.
https://doi.org/10.1182/blood.V130.Suppl_1.1489.1489
Published: 2017
Journal Articles

What Do Patients Prioritize in Selecting Chronic Lymphocytic Leukemia (CLL) Treatments?

Carol Mansfield, PhD, Anthony Masaquel, MPH, PhD, Jessie Sutphin, Elisa S Weiss, PhD, Meghan E. Gutierrez, Jennifer Wilson, Jia Li, PhD, Carolina Reyes, PhD
Journal: Blood
Blood (2016) 128 (22): 1239.
https://doi.org/10.1182/blood.V128.22.1239.1239
Published: 2016
Journal Articles

What Is the Cost-Effectiveness of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Monotherapy for the Treatment of Follicular Lymphoma Patients Who Relapse after or Are Refractory to a Rituximab-Containing Regimen in the US?

Gregory F. Guzauskas, MSPH, PhD, Anthony Masaquel, MPH, PhD, Carolina Reyes, PhD, Kenneth Wilhelm, MD, Tania Krivasi, MSc, David L. Veenstra, PharmD, PhD
Journal: Blood
Blood (2016) 128 (22): 3605.
https://doi.org/10.1182/blood.V128.22.3605.3605
Published: 2016
Journal Articles

Are There Differences in Treatment Patterns, Cost, and Quality Indicators By Site of Care for First Line Treatment for Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (NHL/CLL)?

Adrianne W Casebeer, MPP, MS, PhD, Sari Hopson, MSPH, PhD, Dana A Drzayich Jankus, MS, Zhuliang Tao, MSPH, Stephen Stemkowski, MHA, PhD, Andrew Howe, PharmD, BA, Jeffrey Patton, MD, Art Small, MD, Anthony Masaquel, MPH, PhD
Journal: Blood
Blood (2015) 126 (23): 3298.
https://doi.org/10.1182/blood.V126.23.3298.3298
Published: 2015